nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.0366	0.174	CbGeAlD
Lurasidone—HTR7—vagus nerve—peripheral nervous system neoplasm	0.0201	0.0953	CbGeAlD
Lurasidone—HTR7—cranial nerve—peripheral nervous system neoplasm	0.0153	0.0726	CbGeAlD
Lurasidone—HTR7—pons—peripheral nervous system neoplasm	0.0151	0.0718	CbGeAlD
Lurasidone—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.0134	0.0636	CbGeAlD
Lurasidone—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.0125	0.0595	CbGeAlD
Lurasidone—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.00953	0.0453	CbGeAlD
Lurasidone—HTR2A—pons—peripheral nervous system neoplasm	0.00942	0.0448	CbGeAlD
Lurasidone—HTR1A—ganglion—peripheral nervous system neoplasm	0.00809	0.0385	CbGeAlD
Lurasidone—HTR7—nerve—peripheral nervous system neoplasm	0.00783	0.0372	CbGeAlD
Lurasidone—HTR7—ganglion—peripheral nervous system neoplasm	0.00774	0.0368	CbGeAlD
Lurasidone—DRD2—nerve—peripheral nervous system neoplasm	0.00741	0.0352	CbGeAlD
Lurasidone—DRD2—ganglion—peripheral nervous system neoplasm	0.00731	0.0348	CbGeAlD
Lurasidone—HTR2A—nerve—peripheral nervous system neoplasm	0.00488	0.0232	CbGeAlD
Lurasidone—HTR2A—ganglion—peripheral nervous system neoplasm	0.00482	0.0229	CbGeAlD
Lurasidone—HTR1A—brainstem—peripheral nervous system neoplasm	0.00352	0.0167	CbGeAlD
Lurasidone—ADRA2C—trigeminal ganglion—peripheral nervous system neoplasm	0.00349	0.0166	CbGeAlD
Lurasidone—HTR7—brainstem—peripheral nervous system neoplasm	0.00336	0.016	CbGeAlD
Lurasidone—ADRA2C—parotid gland—peripheral nervous system neoplasm	0.00329	0.0157	CbGeAlD
Lurasidone—DRD2—brainstem—peripheral nervous system neoplasm	0.00318	0.0151	CbGeAlD
Lurasidone—ADRA2A—trigeminal ganglion—peripheral nervous system neoplasm	0.00279	0.0132	CbGeAlD
Lurasidone—HTR2A—brainstem—peripheral nervous system neoplasm	0.0021	0.00996	CbGeAlD
Lurasidone—HTR1A—cerebellum—peripheral nervous system neoplasm	0.00173	0.00824	CbGeAlD
Lurasidone—HTR7—cerebellum—peripheral nervous system neoplasm	0.00166	0.00788	CbGeAlD
Lurasidone—DRD2—cerebellum—peripheral nervous system neoplasm	0.00157	0.00745	CbGeAlD
Lurasidone—ADRA2C—cerebellum—peripheral nervous system neoplasm	0.00152	0.00724	CbGeAlD
Lurasidone—ADRA2A—cerebellum—peripheral nervous system neoplasm	0.00122	0.00578	CbGeAlD
Lurasidone—HTR2A—cerebellum—peripheral nervous system neoplasm	0.00103	0.00491	CbGeAlD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000729	0.000947	CcSEcCtD
Lurasidone—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000728	0.000946	CcSEcCtD
Lurasidone—Hot flush—Doxorubicin—peripheral nervous system neoplasm	0.000727	0.000945	CcSEcCtD
Lurasidone—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000727	0.000944	CcSEcCtD
Lurasidone—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000726	0.000943	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000725	0.000942	CcSEcCtD
Lurasidone—Increased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000724	0.00094	CcSEcCtD
Lurasidone—Menopausal symptoms—Doxorubicin—peripheral nervous system neoplasm	0.000721	0.000936	CcSEcCtD
Lurasidone—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00072	0.000936	CcSEcCtD
Lurasidone—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00072	0.000936	CcSEcCtD
Lurasidone—Insomnia—Vincristine—peripheral nervous system neoplasm	0.00072	0.000935	CcSEcCtD
Lurasidone—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000718	0.000932	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000713	0.000926	CcSEcCtD
Lurasidone—Malaise—Etoposide—peripheral nervous system neoplasm	0.000712	0.000925	CcSEcCtD
Lurasidone—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000712	0.000925	CcSEcCtD
Lurasidone—Vertigo—Etoposide—peripheral nervous system neoplasm	0.000709	0.000922	CcSEcCtD
Lurasidone—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000707	0.000918	CcSEcCtD
Lurasidone—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000704	0.000915	CcSEcCtD
Lurasidone—Infection—Cisplatin—peripheral nervous system neoplasm	0.000699	0.000908	CcSEcCtD
Lurasidone—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000698	0.000907	CcSEcCtD
Lurasidone—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000694	0.000902	CcSEcCtD
Lurasidone—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000694	0.000902	CcSEcCtD
Lurasidone—Lethargy—Doxorubicin—peripheral nervous system neoplasm	0.000694	0.000902	CcSEcCtD
Lurasidone—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000693	0.0009	CcSEcCtD
Lurasidone—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000693	0.0009	CcSEcCtD
Lurasidone—Rash—Topotecan—peripheral nervous system neoplasm	0.000692	0.0009	CcSEcCtD
Lurasidone—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000692	0.000899	CcSEcCtD
Lurasidone—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000692	0.000899	CcSEcCtD
Lurasidone—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.00069	0.000896	CcSEcCtD
Lurasidone—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.000689	0.000895	CcSEcCtD
Lurasidone—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000687	0.000892	CcSEcCtD
Lurasidone—Rash—Tretinoin—peripheral nervous system neoplasm	0.000687	0.000892	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000687	0.000892	CcSEcCtD
Lurasidone—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000687	0.000892	CcSEcCtD
Lurasidone—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000686	0.000892	CcSEcCtD
Lurasidone—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000686	0.000892	CcSEcCtD
Lurasidone—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000686	0.000891	CcSEcCtD
Lurasidone—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000684	0.000889	CcSEcCtD
Lurasidone—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000684	0.000888	CcSEcCtD
Lurasidone—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000683	0.000888	CcSEcCtD
Lurasidone—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000682	0.000886	CcSEcCtD
Lurasidone—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.00068	0.000884	CcSEcCtD
Lurasidone—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.00068	0.000884	CcSEcCtD
Lurasidone—Rash—Melphalan—peripheral nervous system neoplasm	0.000678	0.000881	CcSEcCtD
Lurasidone—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000677	0.00088	CcSEcCtD
Lurasidone—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000675	0.000877	CcSEcCtD
Lurasidone—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000671	0.000872	CcSEcCtD
Lurasidone—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000671	0.000872	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000668	0.000867	CcSEcCtD
Lurasidone—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000664	0.000863	CcSEcCtD
Lurasidone—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000657	0.000854	CcSEcCtD
Lurasidone—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000657	0.000854	CcSEcCtD
Lurasidone—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000653	0.000848	CcSEcCtD
Lurasidone—Nausea—Topotecan—peripheral nervous system neoplasm	0.000652	0.000847	CcSEcCtD
Lurasidone—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000651	0.000845	CcSEcCtD
Lurasidone—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.00065	0.000845	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000648	0.000842	CcSEcCtD
Lurasidone—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000647	0.000841	CcSEcCtD
Lurasidone—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000647	0.000841	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000641	0.000833	CcSEcCtD
Lurasidone—Infection—Etoposide—peripheral nervous system neoplasm	0.00064	0.000832	CcSEcCtD
Lurasidone—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000639	0.00083	CcSEcCtD
Lurasidone—Nausea—Melphalan—peripheral nervous system neoplasm	0.000639	0.00083	CcSEcCtD
Lurasidone—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000637	0.000828	CcSEcCtD
Lurasidone—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000635	0.000825	CcSEcCtD
Lurasidone—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000635	0.000825	CcSEcCtD
Lurasidone—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000629	0.000817	CcSEcCtD
Lurasidone—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.000629	0.000817	CcSEcCtD
Lurasidone—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000629	0.000817	CcSEcCtD
Lurasidone—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000627	0.000815	CcSEcCtD
Lurasidone—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000626	0.000813	CcSEcCtD
Lurasidone—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000623	0.000809	CcSEcCtD
Lurasidone—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000621	0.000807	CcSEcCtD
Lurasidone—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000621	0.000807	CcSEcCtD
Lurasidone—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000619	0.000804	CcSEcCtD
Lurasidone—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000615	0.000798	CcSEcCtD
Lurasidone—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000611	0.000794	CcSEcCtD
Lurasidone—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000609	0.000792	CcSEcCtD
Lurasidone—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000608	0.00079	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000607	0.000789	CcSEcCtD
Lurasidone—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000602	0.000782	CcSEcCtD
Lurasidone—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000602	0.000782	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.0006	0.000779	CcSEcCtD
Lurasidone—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000594	0.000772	CcSEcCtD
Lurasidone—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000594	0.000772	CcSEcCtD
Lurasidone—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000592	0.00077	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000588	0.000764	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000588	0.000764	CcSEcCtD
Lurasidone—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000584	0.000759	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000582	0.000756	CcSEcCtD
Lurasidone—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000578	0.000751	CcSEcCtD
Lurasidone—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000575	0.000746	CcSEcCtD
Lurasidone—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000573	0.000745	CcSEcCtD
Lurasidone—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000573	0.000744	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000573	0.000744	CcSEcCtD
Lurasidone—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000571	0.000742	CcSEcCtD
Lurasidone—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000566	0.000736	CcSEcCtD
Lurasidone—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000566	0.000736	CcSEcCtD
Lurasidone—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000566	0.000736	CcSEcCtD
Lurasidone—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000565	0.000734	CcSEcCtD
Lurasidone—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000561	0.000729	CcSEcCtD
Lurasidone—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.00056	0.000728	CcSEcCtD
Lurasidone—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000557	0.000723	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000556	0.000723	CcSEcCtD
Lurasidone—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000556	0.000722	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000551	0.000715	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.00055	0.000714	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.00055	0.000714	CcSEcCtD
Lurasidone—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000546	0.000709	CcSEcCtD
Lurasidone—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000544	0.000707	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000536	0.000696	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000535	0.000695	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00053	0.000689	CcSEcCtD
Lurasidone—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000529	0.000687	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000529	0.000687	CcSEcCtD
Lurasidone—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000527	0.000685	CcSEcCtD
Lurasidone—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000526	0.000683	CcSEcCtD
Lurasidone—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000525	0.000682	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000524	0.000681	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000524	0.000681	CcSEcCtD
Lurasidone—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000521	0.000676	CcSEcCtD
Lurasidone—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00052	0.000676	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000518	0.000673	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000515	0.000669	CcSEcCtD
Lurasidone—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000509	0.000662	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000509	0.000662	CcSEcCtD
Lurasidone—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000506	0.000657	CcSEcCtD
Lurasidone—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000505	0.000656	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000502	0.000652	CcSEcCtD
Lurasidone—Rash—Vincristine—peripheral nervous system neoplasm	0.000502	0.000652	CcSEcCtD
Lurasidone—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000501	0.000651	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.0005	0.000649	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000498	0.000648	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000496	0.000644	CcSEcCtD
Lurasidone—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00049	0.000637	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000489	0.000635	CcSEcCtD
Lurasidone—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000481	0.000625	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000479	0.000622	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000475	0.000617	CcSEcCtD
Lurasidone—Nausea—Vincristine—peripheral nervous system neoplasm	0.000473	0.000614	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000472	0.000613	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000465	0.000604	CcSEcCtD
Lurasidone—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000462	0.000601	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000462	0.000601	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000461	0.000599	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000461	0.000599	CcSEcCtD
Lurasidone—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000456	0.000592	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000454	0.00059	CcSEcCtD
Lurasidone—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000447	0.000581	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000445	0.000579	CcSEcCtD
Lurasidone—Rash—Cisplatin—peripheral nervous system neoplasm	0.000444	0.000576	CcSEcCtD
Lurasidone—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000443	0.000576	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000443	0.000575	CcSEcCtD
Lurasidone—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000441	0.000573	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.00044	0.000571	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000437	0.000567	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000436	0.000567	CcSEcCtD
Lurasidone—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000428	0.000556	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000427	0.000555	CcSEcCtD
Lurasidone—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000426	0.000554	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000426	0.000553	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.00042	0.000546	CcSEcCtD
Lurasidone—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000418	0.000543	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000417	0.000542	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000412	0.000536	CcSEcCtD
Lurasidone—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00041	0.000532	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.00041	0.000532	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000409	0.000532	CcSEcCtD
Lurasidone—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000407	0.000528	CcSEcCtD
Lurasidone—Rash—Etoposide—peripheral nervous system neoplasm	0.000406	0.000528	CcSEcCtD
Lurasidone—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000406	0.000527	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000404	0.000524	CcSEcCtD
Lurasidone—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000399	0.000519	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000398	0.000517	CcSEcCtD
Lurasidone—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000397	0.000516	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000396	0.000515	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000396	0.000515	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000394	0.000512	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000389	0.000505	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000386	0.000501	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000383	0.000498	CcSEcCtD
Lurasidone—Nausea—Etoposide—peripheral nervous system neoplasm	0.000383	0.000497	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000382	0.000497	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000379	0.000492	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000377	0.00049	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000376	0.000489	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000376	0.000488	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000374	0.000486	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000369	0.00048	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000369	0.000479	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000368	0.000478	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000367	0.000477	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000367	0.000476	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.00036	0.000468	CcSEcCtD
Lurasidone—Infection—Epirubicin—peripheral nervous system neoplasm	0.000359	0.000466	CcSEcCtD
Lurasidone—Shock—Epirubicin—peripheral nervous system neoplasm	0.000355	0.000462	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000355	0.000461	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000354	0.00046	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000354	0.000459	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000353	0.000458	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000351	0.000456	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000349	0.000454	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000349	0.000453	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000451	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000346	0.00045	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000341	0.000443	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000338	0.000439	CcSEcCtD
Lurasidone—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000332	0.000431	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000329	0.000428	CcSEcCtD
Lurasidone—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000329	0.000427	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000328	0.000426	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000327	0.000425	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000326	0.000424	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000325	0.000422	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000323	0.00042	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000322	0.000418	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000321	0.000417	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000318	0.000413	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000314	0.000408	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000312	0.000406	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000312	0.000405	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000311	0.000405	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.000396	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000302	0.000393	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.000387	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000297	0.000386	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000295	0.000384	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000294	0.000382	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.000378	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000289	0.000375	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.000374	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000286	0.000371	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.000355	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000264	0.000343	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000337	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000256	0.000332	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000321	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000312	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000239	0.00031	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000236	0.000307	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000298	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000297	CcSEcCtD
Lurasidone—Rash—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000296	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000296	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000221	0.000287	CcSEcCtD
Lurasidone—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000279	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.000276	CcSEcCtD
Lurasidone—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000274	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000274	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000258	CcSEcCtD
Lurasidone—ADRA2C—Signaling by GPCR—NTS—peripheral nervous system neoplasm	5.62e-05	0.00282	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	5.62e-05	0.00282	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	5.57e-05	0.0028	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	5.53e-05	0.00278	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.5e-05	0.00276	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	5.49e-05	0.00275	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CD55—peripheral nervous system neoplasm	5.39e-05	0.00271	CbGpPWpGaD
Lurasidone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	5.25e-05	0.00264	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	5.1e-05	0.00256	CbGpPWpGaD
Lurasidone—HTR1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	5.09e-05	0.00255	CbGpPWpGaD
Lurasidone—HTR1A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	5.09e-05	0.00255	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	5.03e-05	0.00252	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	5.02e-05	0.00252	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.93e-05	0.00247	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.89e-05	0.00246	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.85e-05	0.00243	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.81e-05	0.00242	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—IFNB1—peripheral nervous system neoplasm	4.75e-05	0.00238	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	4.74e-05	0.00238	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.69e-05	0.00236	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.63e-05	0.00233	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.57e-05	0.00229	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.47e-05	0.00224	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.46e-05	0.00224	CbGpPWpGaD
Lurasidone—HTR1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	4.45e-05	0.00223	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.44e-05	0.00223	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	4.41e-05	0.00221	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—KNG1—peripheral nervous system neoplasm	4.4e-05	0.00221	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.4e-05	0.00221	CbGpPWpGaD
Lurasidone—HTR2A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	4.39e-05	0.0022	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.38e-05	0.0022	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	4.31e-05	0.00216	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—VIP—peripheral nervous system neoplasm	4.26e-05	0.00214	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.26e-05	0.00214	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.19e-05	0.0021	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	4.07e-05	0.00204	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4e-05	0.00201	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—GNS—peripheral nervous system neoplasm	3.97e-05	0.00199	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.93e-05	0.00197	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.91e-05	0.00196	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	3.88e-05	0.00195	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.87e-05	0.00194	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—IFNB1—peripheral nervous system neoplasm	3.86e-05	0.00194	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—GNAS—peripheral nervous system neoplasm	3.85e-05	0.00193	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.85e-05	0.00193	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.81e-05	0.00191	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—NME1—peripheral nervous system neoplasm	3.81e-05	0.00191	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.81e-05	0.00191	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—HGF—peripheral nervous system neoplasm	3.67e-05	0.00184	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—COX2—peripheral nervous system neoplasm	3.67e-05	0.00184	CbGpPWpGaD
Lurasidone—HTR7—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	3.59e-05	0.0018	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—KNG1—peripheral nervous system neoplasm	3.58e-05	0.0018	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.57e-05	0.00179	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	3.52e-05	0.00177	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.51e-05	0.00176	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.51e-05	0.00176	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.5e-05	0.00176	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.46e-05	0.00174	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.43e-05	0.00172	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	3.39e-05	0.0017	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.32e-05	0.00167	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.29e-05	0.00165	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.24e-05	0.00163	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GNS—peripheral nervous system neoplasm	3.23e-05	0.00162	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.2e-05	0.0016	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.19e-05	0.0016	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—GNAS—peripheral nervous system neoplasm	3.13e-05	0.00157	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NME1—peripheral nervous system neoplasm	3.09e-05	0.00155	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	3.08e-05	0.00155	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.02e-05	0.00151	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—HGF—peripheral nervous system neoplasm	2.98e-05	0.0015	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—COX2—peripheral nervous system neoplasm	2.98e-05	0.00149	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.97e-05	0.00149	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.89e-05	0.00145	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.88e-05	0.00144	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.85e-05	0.00143	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.84e-05	0.00143	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.82e-05	0.00141	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.78e-05	0.0014	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.7e-05	0.00135	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—PTPN11—peripheral nervous system neoplasm	2.68e-05	0.00134	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.61e-05	0.00131	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.6e-05	0.00131	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.59e-05	0.0013	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.53e-05	0.00127	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.53e-05	0.00127	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.52e-05	0.00126	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.52e-05	0.00126	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.48e-05	0.00125	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.43e-05	0.00122	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.43e-05	0.00122	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ENO2—peripheral nervous system neoplasm	2.41e-05	0.00121	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.4e-05	0.00121	CbGpPWpGaD
Lurasidone—DRD2—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	2.34e-05	0.00117	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.32e-05	0.00117	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.29e-05	0.00115	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.28e-05	0.00115	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.28e-05	0.00115	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.26e-05	0.00113	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.26e-05	0.00113	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.25e-05	0.00113	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.21e-05	0.00111	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.21e-05	0.00111	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—PTPN11—peripheral nervous system neoplasm	2.17e-05	0.00109	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.17e-05	0.00109	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.14e-05	0.00107	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.11e-05	0.00106	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	2.08e-05	0.00105	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.08e-05	0.00104	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.07e-05	0.00104	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.05e-05	0.00103	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.05e-05	0.00103	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—BCHE—peripheral nervous system neoplasm	2.03e-05	0.00102	CbGpPWpGaD
Lurasidone—ADRA2C—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	2.02e-05	0.00101	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.01e-05	0.00101	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.98e-05	0.000996	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.98e-05	0.000992	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.97e-05	0.00099	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ENO2—peripheral nervous system neoplasm	1.96e-05	0.000981	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.94e-05	0.000974	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—TH—peripheral nervous system neoplasm	1.91e-05	0.00096	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.9e-05	0.000955	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.89e-05	0.000947	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.82e-05	0.000914	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.8e-05	0.000905	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.8e-05	0.000901	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.75e-05	0.000876	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—BCHE—peripheral nervous system neoplasm	1.65e-05	0.000829	CbGpPWpGaD
Lurasidone—ADRA2A—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.64e-05	0.000822	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—NRAS—peripheral nervous system neoplasm	1.61e-05	0.000808	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.59e-05	0.000797	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.58e-05	0.000795	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.58e-05	0.000791	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—GNAS—peripheral nervous system neoplasm	1.56e-05	0.000784	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.56e-05	0.000782	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—TH—peripheral nervous system neoplasm	1.55e-05	0.00078	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.54e-05	0.000774	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.54e-05	0.000771	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ABCB1—peripheral nervous system neoplasm	1.53e-05	0.000769	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.49e-05	0.000749	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.47e-05	0.000738	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.42e-05	0.000714	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.42e-05	0.000711	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.39e-05	0.000699	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.38e-05	0.00069	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.37e-05	0.000688	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.35e-05	0.00068	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.35e-05	0.000677	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.33e-05	0.000669	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.32e-05	0.000662	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—NRAS—peripheral nervous system neoplasm	1.31e-05	0.000656	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.31e-05	0.000655	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.29e-05	0.000648	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.29e-05	0.000646	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.27e-05	0.000638	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.27e-05	0.000637	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GNAS—peripheral nervous system neoplasm	1.27e-05	0.000636	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.27e-05	0.000635	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.25e-05	0.000626	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ABCB1—peripheral nervous system neoplasm	1.24e-05	0.000625	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—TP53—peripheral nervous system neoplasm	1.23e-05	0.000618	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.21e-05	0.000609	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.18e-05	0.000595	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—HRAS—peripheral nervous system neoplasm	1.18e-05	0.000591	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.17e-05	0.000585	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.16e-05	0.00058	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.06e-05	0.000532	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—AKT1—peripheral nervous system neoplasm	1.04e-05	0.000522	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1e-05	0.000502	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—TP53—peripheral nervous system neoplasm	1e-05	0.000502	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—HRAS—peripheral nervous system neoplasm	9.56e-06	0.00048	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.54e-06	0.000479	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	9.42e-06	0.000473	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.38e-06	0.000471	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.24e-06	0.000463	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	9.16e-06	0.00046	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.08e-06	0.000456	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.07e-06	0.000455	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	8.44e-06	0.000424	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.38e-06	0.000421	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	8.33e-06	0.000418	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	8.32e-06	0.000417	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.25e-06	0.000414	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.23e-06	0.000413	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.1e-06	0.000407	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.61e-06	0.000382	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.5e-06	0.000376	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.41e-06	0.000372	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.37e-06	0.00037	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.17e-06	0.00036	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.09e-06	0.000356	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	7.04e-06	0.000353	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.98e-06	0.00035	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.79e-06	0.000341	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.76e-06	0.000339	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.73e-06	0.000338	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.72e-06	0.000337	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.62e-06	0.000332	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.57e-06	0.00033	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.51e-06	0.000327	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.51e-06	0.000327	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.4e-06	0.000321	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.17e-06	0.000309	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.13e-06	0.000308	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.03e-06	0.000303	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.97e-06	0.000299	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.96e-06	0.000299	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.91e-06	0.000296	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.87e-06	0.000294	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.82e-06	0.000292	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.82e-06	0.000292	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.81e-06	0.000292	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.64e-06	0.000283	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.57e-06	0.000279	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.49e-06	0.000275	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.46e-06	0.000274	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.41e-06	0.000272	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.4e-06	0.000271	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.34e-06	0.000268	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.33e-06	0.000267	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5.3e-06	0.000266	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.29e-06	0.000265	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.25e-06	0.000264	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.08e-06	0.000255	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.95e-06	0.000248	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.91e-06	0.000247	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.87e-06	0.000244	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.85e-06	0.000243	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.61e-06	0.000231	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.54e-06	0.000228	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.43e-06	0.000222	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.31e-06	0.000216	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—peripheral nervous system neoplasm	4.21e-06	0.000211	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.17e-06	0.000209	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.13e-06	0.000207	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.12e-06	0.000207	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.99e-06	0.0002	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.79e-06	0.00019	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.73e-06	0.000187	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.64e-06	0.000183	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.62e-06	0.000182	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.56e-06	0.000179	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.52e-06	0.000177	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	3.42e-06	0.000172	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.39e-06	0.00017	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.24e-06	0.000163	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.2e-06	0.00016	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.15e-06	0.000158	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.86e-06	0.000144	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.46e-06	7.32e-05	CbGpPWpGaD
